CULT Food Science Subsidiary Further Foods Submits Trial Design for Cultivated Meat in Pet Food to the FDA

TORONTO — CULT Food Science Corp., a food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry, announced that its subsidiary, Further Foods Inc., has completed and submitted the feeding trial design protocol for dog food products containing cell-cultivated chicken to the FDA.

The trial is anticipated to be a 26-week, minimally invasive study involving 30 healthy, adult dogs of various breeds and ages. The trial will monitor feed intake data, hematology, serum biochemistry, urinalysis, weight, fecal analysis and digestibility factors to ensure the inclusion of cell-cultivated meat is safe for the animals. Further Foods has partnered with Dr. Sarah Dodd to ensure the feeding trial design meets all FDA requirements.

Further Foods intends to begin the feeding trials in Q4 2024, once the FDA is satisfied with the design of the protocol. CULT reported that as far as it is aware, Further Foods is the only company currently in dialogue with the FDA about feeding trials for a cultivated chicken dog treat.

Noochies!, a brand under CULT Food Science, is aiming to be the first-to-market with cultivated meat pet food in North America. This product line aims to provide pet owners with high-quality, ethically produced food options for their pets. The feeding trial is a crucial step towards achieving this goal and ensuring that cultivated meat can be safely and effectively included in pet food products.

Mitchell Scott, CEO of CULT Food Science, said, "Completing and submitting the feeding trial design to the FDA is a critical step towards bringing cultivated meat to the pet food market. A successful trial could significantly change the landscape of pet food, offering nutritional, environmental and ethical benefits for pet owners. We are excited to be at the forefront of this innovation and look forward to advancing this trial in collaboration with Dr. Sarah Dodd and the FDA."